NICE rejects ACI tech for knee cartilage repair
This article was originally published in Clinica
Autologous chondrocyte implantation (ACI) should not be used for the treatment of articular cartilage defects, except where the treatment is part of a clinical study. So says the UK's National Institute for Health and Clinical Excellence (NICE), in an update of its December 2000 guidance on the technology, on the basis that "the evidence does not support the introduction of the technology into the NHS [in England and Wales] at this time."
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.